Thermo Fisher Scientific

Current directors and officers who also hold a role at another S&P 500 company.

• Frederick M. LoweryDD · DirectorHSIC · CEO
• Michel LagardeVRTX · DirectorWST · CEO
• C. Martin HarrisCL · Director
• Dion J. WeislerINTC · Director
• Gianluca PettitiHPQ · Director
• Jennifer M. JohnsonBEN · CEO
• Karen S. LynchADP · Director
• Nelson ChaiCB · Director
• Ruby R. ChandyDD · Director
• Stephen WilliamsonHON · Director
• Tyler JacksAMGN · Director

Latest Schedule 13D/13G filing per holder. Holders that reported falling below 5% are not shown. Index funds usually report once a year.

• FMR LLCSched. 13G · as of Sep 30, 2026 · filing
  6.00%
  22,261,362 shares

Open-market purchases and sales reported on Form 4. Grants, option exercises and tax withholding are excluded.

Every 8-K with Item 5.02 (departure, election or appointment of directors and officers). The text is the first paragraph of the item.

1. Oct 30, 2026

   On October 27, 2026, Thermo Fisher Scientific Inc. (the “Company”), announced that Michael D. Shafer, Executive Vice President of the Company, will retire effective December 31, 2026. 2

   Read the 8-K filing
2. Jan 12, 2026

   Each of Michel Lagarde and Frederick M. Lowery have notified Thermo Fisher Scientific Inc. (the “Company”) of their decisions to leave the Company to pursue other opportunities. Mr. Lagarde, who has served as Executive Vice President and Chief Operating Officer of the Company since 2021 will depart on March 31, 2026, and Mr. Lowery, who has served as an Executive Vice President of the Company since 2024 will depart on February 28, 2026. Effective March 1, 2026, Thermo Fisher Scientific will update its organizational structure and leadership team. Marc N. Casper will become Chairman and Chief Executive Officer. Gianluca Pettiti, currently an Executive Vice President, will be promoted and transition to the role of President and Chief Operating Officer.

   Read the 8-K filing
3. Jul 23, 2025

   On July 23, 2025, Thermo Fisher Scientific Inc. (the “Company”), announced that Stephen Williamson, Senior Vice President and Chief Financial Officer (CFO) will retire effective March 31, 2026. The Company also announced that the Board of Directors approved the appointment of James R. Meyer, 46, currently Vice President, Financial Operations of the Company, to succeed Williamson as Senior Vice President and CFO of the Company, effective March 1, 2026. Mr. Meyer joined Thermo Fisher in July 2009 and has served in a number of finance roles of increasing responsibility across the Company, including as Vice President of Finance, Customer Channels from April 2020 to December 2022, before assuming his current role in January 2023. Prior to joining Thermo Fisher, Mr. Meyer worked for PricewaterhouseCoopers. 2

   Read the 8-K filing
4. May 22, 2025

   On May 21, 2025, the Board of Directors (the “Board”) of Thermo Fisher Scientific Inc. (the “Company”), following a thorough evaluation, approved the grant of 5-year cliff vesting performance-based restricted stock units (the “Award”) to Marc N. Casper, the Company’s Chairman, President and Chief Executive Officer (“CEO”), to secure his continued leadership through at least May 2030, and to drive substantial returns to shareholders through total shareholder return (“TSR”) outperformance over the long-term. The Board has determined that securing Mr. Casper’s continued leadership through at least May 2030 is in the best interests of shareholders as evidenced by his long-term track record of success in executing the Company’s growth and capital deployment strategy through a variety of macroeconomic environments. Through Mr.

   Read the 8-K filing
5. Feb 19, 2025

   On February 19, 2025, the Board of Directors (the “Board”) of Thermo Fisher Scientific Inc. (the “Company”) increased its size to twelve members and elected Karen S. Lynch as a director of the Company, effective February 19, 2025, for a term expiring at the Company’s 2025 annual meeting. The Board anticipates that Ms. Lynch will serve on the Audit Committee following re-election at the Company’s 2025 annual meeting. Ms. Lynch is a seasoned health care executive who has over three decades of experience in the industry. As the former president and chief executive officer of CVS Health Corporation (NYSE: CVS) (“CVS Health”), a leading health solutions company, where she was responsible for leading more than 300,000 employees. Under Ms.

   Read the 8-K filing
6. Sep 21, 2023

   On July 13, 2023, Thermo Fisher Scientific Inc. (the “Company”) filed a Current Report on Form 8-K to announce the election of Jennifer “Jenny” Johnson as a director of the Company. At the time of such filing, the Board of Directors had not yet determined committee assignments for Ms. Johnson. On September 21, 2023, the Board of Directors appointed Ms. Johnson to the Audit Committee, effective as of that date. 2

   Read the 8-K filing
7. Jul 13, 2023

   On July 13, 2023, the Board of Directors (the “Board”) of Thermo Fisher Scientific Inc. (the “Company”) increased its size to twelve members and elected Jennifer “Jenny” Johnson, president and chief executive officer of Franklin Resources, Inc., as a director of the Company, effective July 13, 2023, for a term expiring at the Company’s 2024 annual meeting. In a career at Franklin Templeton spanning 35 years, Ms. Johnson has been a key driver in the company's transformation to what is now one of the largest global asset managers with over $1.4 trillion in assets under management. Ms. Johnson has held leadership roles in all major divisions of the business, including investment management, distribution, technology, operations and wealth management, before becoming CEO in February 2020. Ms. Johnson is also a board member of Franklin Resources, Inc.

   Read the 8-K filing
8. May 26, 2023

   Amended and Restated 2013 Stock Incentive Plan On May 24, 2023, at the Thermo Fisher Scientific Inc. (the “Company”) annual meeting of shareholders (the “Annual Meeting”), as further described in

   Read the 8-K filing
9. Nov 14, 2022

   Amendment of Compensatory Arrangements On November 10, 2022, the Compensation Committee of the Board of Directors of the Registrant (the “Committee”) approved amendments to certain of the equity compensation agreements of Marc N. Casper, the Registrant’s Chairman, President and Chief Executive Officer, to align the retirement vesting provisions in Mr. Casper’s equity award agreements with those granted to all other officers of the Registrant. The amended provisions relate to the vesting and exercise of his equity awards in the event of retirement. In approving the amendments to Mr. Casper’s equity compensation agreements, the Committee determined that aligning the terms of Mr. Casper’s awards with those of other members of the Registrant’s management team was appropriate and in the best interests of the Registrant and its stockholders.

   Read the 8-K filing
10. Feb 24, 2022

    On February 23, 2022, the Board of Directors of Thermo Fisher Scientific Inc. (the “Company”) increased the size of its board to thirteen members and elected Ruby R. Chandy as a director of the Company for a term expiring at the Company’s 2022 annual meeting, both effective as of March 1, 2022. Ms. Chandy will serve on the Audit Committee of the Board. Ms. Chandy was the president of the Industrial Division of Pall Corporation, a leading supplier of filtration, separation, and purification technologies. Previously, Ms. Chandy was chief marketing officer at the Dow Chemical Company and Rohm and Haas Corporation. Ms. Chandy currently serves on the board of directors of DuPont de Nemours, Inc. and Flowserve Corporation.

    Read the 8-K filing
11. Sep 28, 2021

    On September 23, 2021, Mark Stevenson, Executive Vice President and Chief Operating Officer of Thermo Fisher Scientific Inc. (the “Company”), notified the Company of his decision to retire effective March 18, 2022, and Syed Jafry, Senior Vice President, Regions, notified the Company of his decision to retire effective March 31, 2022. Also on September 23, 2021 the Board of Directors of the Company appointed Michel Lagarde, currently Executive Vice President, Executive Vice President and Chief Operating Officer, effective January 1, 2022. Mr. Lagarde, 47, was appointed Executive Vice President in September 2019. Mr. Lagarde was President of the Company’s Pharma Services business from August 2017 to September 2019 and previously served as President of Patheon N.V.

    Read the 8-K filing
12. Nov 20, 2020

    On November 20, 2020, the Board of Directors of Thermo Fisher Scientific Inc. (the “Company”), elected R. Alexandra Keith as a director of the Company for a term expiring at the 2021 annual meeting. Ms. Keith is the Chief Executive Officer of Procter & Gamble’s (“P&G”) global Beauty business, based in Geneva, Switzerland, and sits on P&G's Global Leadership Council. In her current role, she oversees a $13 billion business with 10,000 employees around the world. Alex has spent her entire 30-year career at P&G in a variety of roles including manufacturing, logistics, communications and product innovation. In connection with her service as a director, Ms.

    Read the 8-K filing
13. Sep 14, 2020

    On September 10, 2020, Peter Hornstra, Vice President and Chief Accounting Officer of Thermo Fisher Scientific Inc. (the “Company”), notified the Company that he will retire effective March 31, 2021. Also on September 10, 2020, the Board of Directors of the Company elected Joseph Holmes, 41, currently Senior Director of Technical Accounting, to the position of Vice President and Chief Accounting Officer of the Company, effective March 31, 2021. Mr. Holmes joined Thermo Fisher in his current role in June 2017 and leads a team that provides a broad range of accounting and finance counsel to the Company’s global finance team. Previously, Mr. Holmes served as Director, Technical Accounting and Reporting at St.

    Read the 8-K filing
14. Sep 6, 2019

    On September 5, 2019, the Board of Directors of Thermo Fisher Scientific Inc. (the “Company”), elected Debora L. Spar as a director of the Company, effective September 5, 2019, for a term expiring at the 2020 annual meeting. Ms. Spar was appointed to the Board’s Audit Committee. Ms. Spar is currently a Baker Foundation Professor at Harvard Business School, where she returned after serving as President of Barnard College from 2008 to 2017. Prior to her time at Barnard, Ms. Spar was a professor at Harvard Business School for 17 years and served as Senior Associate Dean for Faculty Research and Development. In connection with her service as a director, Ms.

    Read the 8-K filing
15. Feb 28, 2019

    (e) Compensatory Arrangements of Certain Officers On February 26, 2019, the Compensation Committee of the Board of Directors (the "Compensation Committee") of Thermo Fisher Scientific Inc. (the "Company") established a target cash bonus amount for 2019 for each of the Company’s executive officers, as well as performance metrics and goals for the Company under the Company’s annual cash incentive program. The target cash bonus amount for each executive, which is expressed as a percentage of base salary (ranging from 90% to 200%), was determined by the Compensation Committee based on the salary level and position of such executive within the Company.

    Read the 8-K filing

Proxy statements (DEF 14A): 2026 · 2025 · 2024 · 2023 · 2022 · 2021

From the company's 10-K XBRL data (SEC companyfacts).

People who stopped filing as an insider of this company. “Last filing” is the last Form 3/4/5, an upper bound on when they left.